PMID- 29717651
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20181211
IS  - 1744-8301 (Electronic)
IS  - 1479-6694 (Linking)
VI  - 14
IP  - 18
DP  - 2018 Aug
TI  - Efficacy and safety of first-line sunitinib in Chinese patients with metastatic 
      renal cell carcinoma.
PG  - 1835-1845
LID - 10.2217/fon-2017-0733 [doi]
AB  - AIM: We report the first prospective study of sunitinib for metastatic renal cell 
      carcinoma (mRCC) in China. METHODS: Chinese mRCC patients received first-line 
      sunitinib 50 mg daily (4/2 regimen). Overall survival (OS), progression-free 
      survival (PFS), objective response rate and safety were assessed. Potential 
      efficacy biomarkers were explored in post hoc analyses. RESULTS: Median PFS was 
      61.7 weeks; median OS was 133.4 weeks; objective response rate was 31.1%. Most 
      frequent adverse events (AEs) were: hand-foot syndrome (63.8%), decreased white 
      blood cell count (52.4%), fatigue (51.4%) and decreased platelet count (51.4%). 
      AEs were identified that predicted longer PFS and OS. CONCLUSION: Sunitinib 
      showed efficacy and manageable AE profile in treatment-naive Chinese mRCC 
      patients. Larger prospective studies are required to confirm identified AEs as 
      predictors of efficacy.
FAU - Qin, Shu-Kui
AU  - Qin SK
AD  - Department of Medical Oncology, PLA Cancer Center of Nanjing Bayi Hospital, 
      Nanjing, PR China.
FAU - Jin, Jie
AU  - Jin J
AD  - Department of Urology, Peking University First Hospital, Beijing, PR China.
FAU - Guo, Jun
AU  - Guo J
AD  - Department of Renal Cancer & Melanoma, Peking University Cancer Hospital & 
      Institute, Beijing, PR China.
FAU - Wang, Jin-Wan
AU  - Wang JW
AD  - Department of Medical Oncology, Cancer Hospital/Institute, Chinese Academy of 
      Medical Sciences & Peking Union Medical College, Beijing, PR China.
FAU - Zhou, Fang-Jian
AU  - Zhou FJ
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
FAU - Huang, Yi-Ran
AU  - Huang YR
AD  - Department of Urology, Shanghai Renji Hospital, Shanghai, PR China.
FAU - Ren, Xiu-Bao
AU  - Ren XB
AD  - Department of Biology Treatment, Tianjin Medical University Cancer Institute & 
      Hospital, Tianjin, PR China.
FAU - Ye, Ding-Wei
AU  - Ye DW
AD  - Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, PR 
      China.
FAU - Pan, Sharon
AU  - Pan S
AD  - Pfizer, Inc., New York, NY 10017, USA.
FAU - Sajben, Peter
AU  - Sajben P
AD  - Pfizer, Inc., New York, NY 10017, USA.
FAU - Wang, Qiao
AU  - Wang Q
AD  - Pfizer Global Research & Development, Shanghai, PR China.
LA  - eng
PT  - Clinical Trial, Phase IV
PT  - Journal Article
PT  - Multicenter Study
DEP - 20180502
PL  - England
TA  - Future Oncol
JT  - Future oncology (London, England)
JID - 101256629
RN  - 0 (Antineoplastic Agents)
RN  - V99T50803M (Sunitinib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy/mortality
MH  - China
MH  - Female
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/mortality
MH  - Male
MH  - Middle Aged
MH  - Progression-Free Survival
MH  - Sunitinib/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Chinese
OT  - metastasis
OT  - renal cell carcinoma
OT  - sunitinib
OT  - targeted therapy
EDAT- 2018/05/03 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/05/03 06:00
PHST- 2018/05/03 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/05/03 06:00 [entrez]
AID - 10.2217/fon-2017-0733 [doi]
PST - ppublish
SO  - Future Oncol. 2018 Aug;14(18):1835-1845. doi: 10.2217/fon-2017-0733. Epub 2018 
      May 2.